New ‘chemo-switch’ therapy offers new options and better survival rates Related items from OnMedicaFour kidney cancer drugs ruled out by NICEForty-somethings see alarming rise in oral cancers Hospital transport service fails kidney patientsYoung people warned of sunbed cancer risksDialysis patients helped by lowering blood pressure (Source: OnMedica Latest News) Source: MedWorm: Oral Cancer
Tag: Kidney
Oral therapy slows progression of advanced kidney cancer
Pazopanib (Votrient) appears to delay disease progression by 54% in patients with advanced renal cell
carcinoma, according to a study by Italian researchers. (Source: Modern Medicine)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: Advanced, Cancer, Kidney, Oral, Progression, Slows, therapy
Targeted Oral Drug Pazopanib Slows Progression Of Advanced Kidney Cancer
A new study finds that the drug pazopanib (VOTRIENT) slows disease progression by 54 percent in patients with advanced renal cell carcinoma (RCC). This is the first publication of the full data used by the U.S. Food and Drug Administration to approve the drug in October 2009 for the treatment of advanced RCC… (Source: Health News from Medical News Today) Source: MedWorm: Oral Cancer
Tags: Advanced, Cancer, Drug, Kidney, Oral, Pazopanib, Progression, Slows, Targeted